Table 1.
Treatment of neuroinflammation with (D) (added NCS information is italicized)
| Year | NCS [7] | Online supplement [4] | SSC | NIA-AA | NIA-AA + (D) |
|---|---|---|---|---|---|
| 2007 | Stage 2 | Online supplement_6.pdf (p. 2; online suppl. 6 [4]) The patient visited in December 2007 with recent memory disturbance There were no abnormalities in the findings |
Cognitively unimpaired | Stage 2 | Stage 2 |
| 05-02-2008 | Stage 3 | Online supplement_4.pdf (p. 1; online suppl. 4 [4]) MMSE = 23, CERAD = 45, CDR = 0.5/0.5/1.5, MRI; hippocampal atrophy Assessment: MCI, amnestic Plan: observation |
MCI | Stage 3 | Stage 3 |
|
Seoul Study − Trial of DDS for AD prevention DDS supply was suspended in Korea from 2016 | |||||
| 27-06-2018 | Stage 4 | Online supplement_6.pdf (p. 1, p. 2; online suppl. 6 [4]) On 20 June 2018, the patient presented with leg pain and memory impairment The patient scored 22/30 on the MMSE and 4 on the GDS 4, with decreases in time-keeping, memory and calculation ability On 27 June 2018, brain MRI imaging showed multiple lacunar infarction and cerebral cortical atrophy |
Dementia | Stage 4 | Stage 4 |
| 27-06-2018 ˜ Stage 6 | Side effects of (D) prescribed by the doctor | Stage 6 | |||
| 01-10-2018 | Abdominal pain, bradycardia, heart failure, angina pectoris, perineal incontinence, dysphagia, anemia, weight loss, peripheral edema, edema, leg cramps, myalgia, irritability, anxiety progression, convulsions, transient mental disorder, gait abnormality, apathy, dizziness, delusions, increased frequency of dreaming, increased ecstatic mood, pyramidal symptoms, seizures/hypertension, exercise reduction, difficulty breathing, dysuria | ||||
| 10-2018 ˜ | Stage 5 | Stop AAD | |||
| 06-11-2018 | Stage 5 | Online supplement_1.pdf (pages 1–2; online suppl. 1 [4]) MMSE 18/30, CDR 1.0, FAB 16/18, NPI-Q 30, K-IADL 0.6, GDS 3, GSS 0, Lewy bodies 0 |
Dementia | Stage 5 | Stage 5 |
| 06-11-2018 ˜ Stage 6 | Side effects of (D) online supplement_2.pdf (p. 1; online suppl. 2 [4]) | Stage 6 | |||
| 21-11-2018 | Abdominal pain, bradycardia, heart failure, angina pectoris, perineal incontinence, dysphagia, anaemia, weight loss, peripheral edema, edema, leg cramps, myalgia, irritability, anxiety progression, convulsions, transient mental disorder, gait abnormality, apathy, dizziness, delusions, increased frequency of dreaming, increased ecstatic mood, pyramidal symptoms, seizures/ hypertension, exercise reduction, difficulty breathing, dysuria | ||||
| 22-11-2018 | Stage 5 | Stop AAD | Stage 5 | ||
| The Korea Orphan and Essential Drug Center imported and supplied DDS | |||||
| 28-11-2018 | DDS, online supplement_3.pdf (p. 1; online suppl. 3 [4]) The Korea Orphan and Essential Drug Center imported and supplied DDS on 2018-11-28, 2018-12-27, and 2019-04-02 |
||||
| 14-01-2019 | Stage 3 | Online supplement_1.pdf (pp. 3–5; online suppl. 1 [4]) MMSE 17/30, CDR 1.0, FAB 14/18, NPI-Q 0, K-IADL 0.3, GDS 2, GSS 2, Lewy bodies 0 |
MCI | Stage 3 | Stage 3 |
| 01-05-2020 | Stage 3 | DDS supply resumed in Korea in January 2020. The Seoul Study cohort was prescribed 150–300 mg DDS as a competitor for the inflammasome | MCI | Stage 3 | Stage 3 |